The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
The first case reports with the group’s lead Car-T therapy, plus talk of autoimmune diseases and diabetes, prompt a 39% share price surge.
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Ambrx’s PSMA-targeting ADC generated puzzling data at ESMO, but J&J has seen enough to launch a premium-priced buyout.
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.